AR057812A1 - Heterobiciclos nitrogenados con accion sobre l-cpt1. procesos de obtencion y composiciones farmaceuticas - Google Patents
Heterobiciclos nitrogenados con accion sobre l-cpt1. procesos de obtencion y composiciones farmaceuticasInfo
- Publication number
- AR057812A1 AR057812A1 ARP060103990A ARP060103990A AR057812A1 AR 057812 A1 AR057812 A1 AR 057812A1 AR P060103990 A ARP060103990 A AR P060103990A AR P060103990 A ARP060103990 A AR P060103990A AR 057812 A1 AR057812 A1 AR 057812A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- hydroxy
- fluor
- alkoxy
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos inhiben la L-CPT1 y pueden utilizarse como medicamentos. Procesos de obtencion de los mismos y composiciones farmacéuticas. Reivindicacion 1: Compuestos de la formula (1) en la que X es N o CR8; Y es N o CR9; A es - C(R10R11)C(R12R13)-, -C(R10R11)C(R12R13) C(R14R15), -C(R10R11)C(R12R13)C(R14R15)C(R16R17)-, -C(R10R11)C(R12R13)C(R14R15)C(R16R17)C(R18R19)- o -C(R10)=C(R11)-; R1, R2, R3, R4 y R5 con independencia entre sí son hidrogeno, halogeno, ciano, hidroxi, alquilo inferior, fluor-alquilo inferior, alcoxi inferior, fluor-alcoxi inferior, alquilo inferior-C(O), alquilo inferior-C(O)-NH, alquilo inferior-C(O)-N(alquilo inferior), alquilo inferior-S(O)2, NH2-S(O)2, NH2-S(O)2, N(H,alquilo inferior)S-(O)2 o N(alquilo inferior)2-S(O)2, NH2-C(O), N(H,alquilo inferior)-C(O), N(alquilo inferior)2-C(O) o alcoxi inferior-C(O), en los que alquilo inferior está opcionalmente sustituido con hidroxi, alcoxi inferior, NH2, N(H,alquilo inferior) o N(alquilo inferior)2; R6 es hidrogeno, halogeno, alquilo inferior, alcoxi inferior, fluor-alquilo inferior, fluor-alcoxi inferior, hidroxi o hidroxi-alquilo inferior; R7 es hidrogeno, halogeno, hidroxi, ciano, alquilo inferior, alcoxi inferior, fluor-alquilo inferior, fluor-alcoxi inferior o hidroxi-alquilo inferior; R8 es hidrogeno, halogeno, ciano, alquilo inferior, fluor-alquilo inferior, alcoxi inferior, fluor-alcoxi inferior, alquilo inferior-C(O), alquilo inferior-C(O)-NH, alquilo inferior-C(O)- N(alquilo inferior), alquilo inferior-S(O)2, NH2-S(O)2, N(H,alquilo inferior)-S(O)2, N(alquilo inferior)2-S(O)2, NH2-C(O), N(H,alquilo inferior)-C(O), N(alquilo inferior)2-C(O), alcoxi inferior-C(O), COOH, 1H-tetrazolilo, 4H-[1,2,4]oxadiazol-3-il-5- ona, 4H-[1,2,4]tiadiazol-3-il-5- ona, 4H-[1,2,4]oxadiazol-3-il-5-tiona, 3H-[1,2,3,5]oxatiadiazol-4-il2-oxido, SO3H, 3-hidroxi-isooxazolilo, 3-hidroxi-piran-4-on-ilo o P(O) (OCH2CH3)OH, en los que alquilo inferior está opcionalmente sustituido con hidroxi, NH2, N(H,alquilo) inferior o N(alquilo inferior)2 y en los que fluor-alquilo inferior está opcionalmente sustituido con hidroxi; R9 es hidrogeno, halogeno, hidroxi, ciano, alquilo inferior, alcoxi inferior, fluor- alquilo inferior, fluor- alcoxi inferior o hidroxi-alquilo inferior; R10, R11, R12, R13, R14, R15, R16, R17, R18, R19 con independencia entre sí son hidrogeno, halogeno, hidroxi, alquilo inferior, alcoxi inferior, fluor-alquilo inferior, fluor-alcoxi inferior, hidroxi- alquilo inferior o ciano; y las sales y ésteres farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05108468 | 2005-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR057812A1 true AR057812A1 (es) | 2007-12-19 |
Family
ID=37488076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103990A AR057812A1 (es) | 2005-09-15 | 2006-09-13 | Heterobiciclos nitrogenados con accion sobre l-cpt1. procesos de obtencion y composiciones farmaceuticas |
Country Status (13)
Country | Link |
---|---|
US (1) | US7713996B2 (es) |
EP (1) | EP1926711B1 (es) |
JP (1) | JP4843040B2 (es) |
KR (1) | KR101089878B1 (es) |
CN (1) | CN101263116B (es) |
AR (1) | AR057812A1 (es) |
AU (1) | AU2006290803B2 (es) |
BR (1) | BRPI0616246A2 (es) |
CA (1) | CA2621404C (es) |
ES (1) | ES2398111T3 (es) |
IL (1) | IL189663A (es) |
TW (1) | TW200745032A (es) |
WO (1) | WO2007031429A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115990A1 (ja) * | 2004-05-26 | 2005-12-08 | Eisai R & D Management Co., Ltd. | シンナミド化合物 |
US7799933B2 (en) * | 2006-12-21 | 2010-09-21 | Hoffman-La Roche Inc. | Sulfonamide derivatives |
KR100847448B1 (ko) * | 2007-03-22 | 2008-07-21 | 한국화학연구원 | 3-아릴-5-알킬-1,2,4-옥사다이아졸 유도체, 그 제조방법 및이를 포함하는 비만 예방 또는 치료용 조성물 |
KR101140520B1 (ko) * | 2007-06-01 | 2012-04-30 | 에프. 호프만-라 로슈 아게 | 피페리딘-아마이드 유도체 |
WO2009002433A1 (en) * | 2007-06-22 | 2008-12-31 | Dara Biosciences, Inc. | Compositions and methods for treating skin disorders |
JP2011525530A (ja) * | 2008-06-24 | 2011-09-22 | ダラ・バイオサイエンシズ,インコーポレイテッド | 酵素阻害剤およびその使用 |
WO2010017827A1 (en) * | 2008-08-14 | 2010-02-18 | European Molecular Biology Laboratory | 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases |
US9512111B2 (en) | 2010-11-08 | 2016-12-06 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
BR112014028017A2 (pt) | 2012-05-08 | 2017-06-27 | Lycera Corp | composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror |
EP2847198B1 (en) | 2012-05-08 | 2016-12-14 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease |
US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
WO2015131035A1 (en) | 2014-02-27 | 2015-09-03 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods |
US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションLycera Corporation | RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
EP3256450B1 (en) | 2015-02-11 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof |
JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションLycera Corporation | RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物 |
MX2017016134A (es) | 2015-06-11 | 2018-08-15 | Lycera Corp | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. |
JP2018531957A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害薬としての置換二環式ピラゾール化合物及びその使用 |
WO2017075182A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
CN106854172B (zh) * | 2016-12-11 | 2019-04-19 | 山东轩德医药科技有限公司 | 一种6-氟-1h-吲哚-4-甲酸甲酯的制备方法 |
JP2020524718A (ja) * | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドCuradev Pharma Limited | ヒトstingの複素環式小分子調節因子 |
GB2572526A (en) * | 2017-06-22 | 2019-10-09 | Curadev Pharma Ltd | Heterocyclic small molecule modulators of human STING |
US20230226228A1 (en) * | 2020-05-04 | 2023-07-20 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for detection of bacterial infection |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997048697A1 (en) * | 1996-06-19 | 1997-12-24 | Rhone-Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
EP1218336A2 (en) * | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
-
2006
- 2006-09-05 CN CN2006800337894A patent/CN101263116B/zh not_active Expired - Fee Related
- 2006-09-05 CA CA2621404A patent/CA2621404C/en not_active Expired - Fee Related
- 2006-09-05 BR BRPI0616246-0A patent/BRPI0616246A2/pt not_active IP Right Cessation
- 2006-09-05 KR KR1020087008663A patent/KR101089878B1/ko not_active IP Right Cessation
- 2006-09-05 AU AU2006290803A patent/AU2006290803B2/en not_active Ceased
- 2006-09-05 EP EP06793207A patent/EP1926711B1/en not_active Not-in-force
- 2006-09-05 WO PCT/EP2006/065989 patent/WO2007031429A1/en active Application Filing
- 2006-09-05 ES ES06793207T patent/ES2398111T3/es active Active
- 2006-09-05 JP JP2008530471A patent/JP4843040B2/ja not_active Expired - Fee Related
- 2006-09-12 TW TW095133708A patent/TW200745032A/zh unknown
- 2006-09-12 US US11/519,485 patent/US7713996B2/en not_active Expired - Fee Related
- 2006-09-13 AR ARP060103990A patent/AR057812A1/es not_active Application Discontinuation
-
2008
- 2008-02-21 IL IL189663A patent/IL189663A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20070060567A1 (en) | 2007-03-15 |
AU2006290803B2 (en) | 2009-11-26 |
CN101263116A (zh) | 2008-09-10 |
WO2007031429A1 (en) | 2007-03-22 |
KR101089878B1 (ko) | 2011-12-05 |
ES2398111T3 (es) | 2013-03-13 |
IL189663A (en) | 2012-03-29 |
IL189663A0 (en) | 2008-06-05 |
CN101263116B (zh) | 2011-12-07 |
CA2621404A1 (en) | 2007-03-22 |
KR20080046244A (ko) | 2008-05-26 |
BRPI0616246A2 (pt) | 2011-06-14 |
TW200745032A (en) | 2007-12-16 |
EP1926711B1 (en) | 2012-11-07 |
EP1926711A1 (en) | 2008-06-04 |
US7713996B2 (en) | 2010-05-11 |
CA2621404C (en) | 2012-01-24 |
AU2006290803A1 (en) | 2007-03-22 |
JP2009507884A (ja) | 2009-02-26 |
JP4843040B2 (ja) | 2011-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR057812A1 (es) | Heterobiciclos nitrogenados con accion sobre l-cpt1. procesos de obtencion y composiciones farmaceuticas | |
AR059425A1 (es) | Amidas ciclicas condensadas del acido bencensulfonico, un metodo para su preparacion, composiciones farmaceuticas que las contienen y el empleo de las mismas en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de l-cpt1 | |
PE20021004A1 (es) | Derivados de piperidina como inhibidores de la ccr5 | |
AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
UY30440A1 (es) | Nuevos compuestos | |
ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
HN2011003014A (es) | Neocleosidos uracilo espiro ocetano en fecha 16 de noviembre de 2011 se solicita por parte del titular de la invencion modificacion del titulo, ahora se denomina: espironucleosidos uraciclicos oxetanicos | |
PA8591701A1 (es) | Derivados de pirrolopirimidina | |
ECSP045253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
UY29427A1 (es) | Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
ECSP034914A (es) | "azaindoles" | |
CR10376A (es) | Derivados de terfenil para el tratamiento de la enfermedad de alzheimer | |
RS53293B (en) | CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES AND THEIR THERAPY | |
AR031680A1 (es) | Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica | |
TW200608972A (en) | Aryl-pyridine derivatives | |
AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
CR10327A (es) | "PIRIDIN(3-4-b) PIRAZINONAS" | |
AR075050A1 (es) | Dicianopiridinas alquilamino-sustituidas | |
UY31638A1 (es) | Furo[3,2-c]piridina y tieno[3,2-c]piridinas | |
ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
RS54244B1 (en) | NALBUFINE BASED FORMULATIONS AND THEIR USE | |
ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |